A Biomarker Development Trial of Satraplatin in Patients With mCRPC

Article
Conference|Genitourinary Cancers Symposium

William K. Oh, MD, professor of medicine, hematology and medical oncology, urology, The Mount Sinai Hospital, discusses a biomarker development trial of satraplatin in patients with metastatic castrate-resistant prostate cancer.

Clinical Pearls

William K. Oh, MD, professor of medicine, hematology and medical oncology, urology, The Mount Sinai Hospital, discusses a biomarker development trial of satraplatin in patients with metastatic castrate-resistant prostate cancer (mCRPC).

  • Satraplatin is a next-generation chemotherapy drug that will not move forward in development
  • It is known that there is a subset of patients with advanced CRPC that respond to platinum chemotherapy
  • Blood- and tissue-based biomarkers are in development to predict the subset of patients that will respond

<<<

Back to the GU 2014 conference page

Recent Videos
Related Content
FDA Accepts sNDA for Darolutamide Plus ADT in mHSPC

FDA Accepts sNDA for Darolutamide Plus ADT in mHSPC

Jordyn Sava
November 21st 2024
Article

The FDA has accepted a supplemental new drug application for the combination of darolutamide and androgen deprivation therapy for the treatment of patients with metastatic hormone-sensitive prostate cancer.

Read More

Transforming Prostate Cancer Care Through Personalized Medicine

Transforming Prostate Cancer Care Through Personalized Medicine

Jordyn Sava;Adam Weiner, MD
July 1st 2024
Podcast

Adam Weiner, MD, discusses his journey toward becoming an oncologist with a focus in urology in this episode of Emerging Experts.

Listen

Novel immunotherapy FK-PC101 Explored in Prostate Cancer Trial

Novel immunotherapy FK-PC101 Explored in Prostate Cancer Trial

Jordyn Sava
November 18th 2024
Article

The phase 2 CELLVX-230 trial is assessing the potential of FK-PC101 to prevent prostate cancer recurrence and delay additional treatments post-surgery.

Read More

Dizman’s Global Pursuit to Cancer Research and Understanding

Dizman’s Global Pursuit to Cancer Research and Understanding

Jordyn Sava;Nazli Dizman, MD
April 1st 2024
Podcast

In this episode of Emerging Experts, Nazli Dizman, MD, shares the intricacies of her journey towards becoming an oncologist in the United States.

Listen

Real-World CAR T-Cell Therapy Outcomes in DLBCL Reveal Challenges and Disparities

Real-World CAR T-Cell Therapy Outcomes in DLBCL Reveal Challenges and Disparities

Kristie L. Kahl
November 15th 2024
Article

Read More

Exploring New Therapies and Sequencing in Relapsed CLL

Exploring New Therapies and Sequencing in Relapsed CLL

Ariana Pelosci
November 14th 2024
Article

Nicole Lamanna, MD, discussed some of the ongoing clinical trials evaluating new therapies for patients with chronic lymphocytic leukemia.

Read More